High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

Ítems similars

• Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
  per: Mkrtichyan, Mikayel, et al.
  Publicat: (2013)
• A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
  per: Basu, Partha, et al.
  Publicat: (2018)
• Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
  per: Wallecha, Anu, et al.
  Publicat: (2013)
• Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001
  per: Sacco, Joseph J., et al.
  Publicat: (2015)
• Lm-LLO-Based Immunotherapies and HPV-Associated Disease
  per: Anu Wallecha, et al.
  Publicat: (2012-01-01)